Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Anjeso (Meloxicam IV) in Pediatric Postoperative Patients
NCT05315479Phase 4Terminated
- Sponsor
- Baudax Bio
- Start
- Feb 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Anjeso in postoperative pain, sponsored by Baudax Bio. Primary endpoint: Number of Subjects Experiencing an AE at 28 days. Started Feb 2022; status: terminated.
02
Drugs
Anjeso
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT05315479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05315479.